Pancreatic ductal adenocarcinoma, the most common of pancreatic cancers, is extraordinarily lethal, with a 5-year survival rate of just 6 percent. Chemotherapy treatments are poorly effective, in part due to a high degree of drug-resistance to currently used regimens.
In a new study, published online June 6 in Nature, researchers at University of California San Diego School of Medicine and Moores Cancer Center, together with colleagues at Keio University. Read more . . .